Main Page Article Search E-Lerts™ Newsletter: Current E-Lerts™ Newsletter Archives E-Lerts™ Newsletter Recipes Archives Defeat Diabetes® E-Lerts™ Newsletter Subscribe Defeat Diabetes ® News by Daniel H. Rasolt Books You Can Use™ Subscribe to Defeat Diabetes Foundation Mailings
About Diabetes Body Care Children Complications Defeat Diabetes Foundation Drugs    » ACE Inhibitor    » Actos    » Alternative Medicine    » Aspirin    » Avandia    » Byetta    » Drugs    » Exenatide    » Glargine    » Glucophage    » Insulin    » Januvia    » Lantus    » Liraglutide    » Metformin    » Recall    » Research    » Rosiglitazone    » Self-Management    » Statins    » Sulfonylureas    » Victoza Elderly E-Lerts™ Governments & Organizations Health & Fitness Insulin MADDCAP™ Mr. Diabetes® Nutrition Obesity Other Diseases Pregnancy Research Risks Self-Management Supplements Type 1 Warning Signs

 

 

 

     

Drugs » Drugs

Search our News Articles Archives for diabetes and health news. Search by word or phrase.  The latest article will appear first.

Search For:  

Search in all categories / subcategories
Search in current category / subcategory

Investigational Drug Produces Significant Weight Loss for Obese Posted: Friday, July 07, 2006

Investigators reported that — Lorcaserin, an investigational drug for the treatment of obesity, produced weight losses between four and 7.9 pounds (1.8 to 3.6 kg) in a 12-week phase IIb dose-ranging study.

Sanofi's Acomplia (rimonabant) Weight Loss Drug Gets EU Approval Posted: Friday, July 07, 2006

The European Commission has approved 20-mg tablets of rimonabant for use as an adjunct to diet and exercise in the treatment of obese or overweight patients with associated cardiometabolic risk factors such as type 2 diabetes or dyslipidemia.

LDL Cholesterol Below Recommended Levels Is Better Posted: Friday, June 30, 2006

Lowering LDL ("bad") cholesterol levels substantially below currently recommended levels significantly reduces the chances that people with diabetes and heart disease will suffer a stroke or heart attack, researchers report.

New Agent Reduces Risk of Diabetic Retinopathy Posted: Friday, June 23, 2006

A protein kinase C-beta inhibitor reduced the risk of sustained vision loss and progression of diabetic macular edema in two phase III trials, researchers announced.

New Drug Galvus Lowers A1c 2.8% Posted: Friday, June 23, 2006

Galvus, a new once-daily oral treatment option for type 2 diabetes, lowers A1c 2.8% and demonstrates impressive efficacy, especially in patients with poor glycemic control, as well as weight loss benefits in obese patients.

Pfizer, Bayer Partner on Fat Modifier Obesity Drugs Posted: Friday, June 23, 2006

Pfizer is buying exclusive worldwide rights to an experimental class of Bayer obesity drugs.

Investigational Januvia (MSD) Put Through Its Paces for Diabetes Posted: Thursday, June 15, 2006

Researchers reported that, Januvia (sitagliptin), an investigational oral agent for type 2 diabetes, appears to be effective when given as a monotherapy or as an adjunct to Glucophage (metformin) or Actos (pioglitazone). FDA approval expected soon.

New Oral Insulin Shows Safety, Feasibility in Trials Posted: Thursday, June 15, 2006

In the first human trials of oral insulin, the drug acted within 15 minutes and showed 60%-70% of the biopotency of injected insulin, without causing any adverse effects, researchers reported here at the 66th Scientific Sessions of the American Diabetes Association.

Once-Weekly BYETTA (Exenatide) LAR Improves Glucose Control in Patients with Type 2 Diabetes Posted: Thursday, June 15, 2006

Reduces A1c by 2 points and average weight lose of 8 pounds in 15 weeks.

Ten Thousand Patients Using Levemir Insulin Show Improvements in BG Without Weight Gain Posted: Thursday, June 15, 2006

Levemir reduced mean A1C levels by 0.54 percent for type 1 and 0.89 percent for type 2 diabetes patients.

 

 

 

 

 

 Costa Rica Travel Corp. will donate a portion of the proceeds to and is a sponsor of Defeat Diabetes Foundation.